BioNTech faces its biggest post pandemic crisis
BioNTech, once celebrated for its COVID-19 vaccines, is grappling with falling demand, restructuring and the departure of its founders. Can its ambitious cancer trials turn it from a one-hit wonder into a biotech giant?
ORIGINAL SOURCE →via DW News
ADVERTISEMENT
⚡ STAY AHEAD
Events like this, convergence-verified across 689 sources, land in your inbox every Sunday. Free.
GET THE SUNDAY BRIEFING →RELATED · health
- [HEALTH] From crisis to commitment: nursing students' sense of belonging during and immediately after the covid-19 pandemic.
- [HEALTH] In the name of immunity, for the sake of the sacred: An analysis of the Iranian government's response to the COVID-19 ou
- [HEALTH] Who writes the pandemic? State power, individual subjectivity, and the history of the present in China's COVID-19 respon
- [HEALTH] Knowledge, Attitudes, and Practices Regarding Arboviruses at a Human-Wildlife Interface: A Cross-Sectional Study in and
- [HEALTH] How to shore up trust during the "cold-period" between pandemics - closing the public trust gap in pandemic preparedness
- [HEALTH] Evaluation of candidate reference materials for the harmonization of Lassa fever serology.